Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
ImClone Systems and Bristol-Myers Squibb are pulling a supplemental BLA for Erbitux (cetuximab) to treat non-small cell lung cancer, saying they plan to resubmit the application as soon as possible after answering manufacturing questions posed by FDA
You may also be interested in...
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.